



Name	Terry Cheuk-Fung Yip
Affiliation	Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Country	Hong Kong
Major Field	Hepatology

Educational Background

2011-2014 B.Sc. in Statistics, The Chinese University of Hong Kong
 2014-2016 M.Phil. in Risk Management Science, The Chinese University of Hong Kong
 2016-2019 Ph.D. in Medical Sciences, The Chinese University of Hong Kong

Professional Experience

2019-2021 Postdoctoral Fellow, Department of Medicine and Therapeutics, The Chinese University of Hong Kong
 2021-present Assistant Professor, Department of Medicine and Therapeutics, The Chinese University of Hong Kong

Main Scientific Publications

1. Lin H, Li G, Delamarre A, Ahn SH, Zhang X, Kim BK, Liang LY, Lee HW, Wong GL, Yuen PC, Chan HL, Chan SL, Wong VW, de Lédinghen V, Kim SU, **Yip TC**. A Liver Stiffness-Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol*. 2023. doi: 10.1016/j.cgh.2023.11.005. Epub ahead of print.
2. **Yip TC**, Wong VW, Lai MS, Lai JC, Tse YK, Liang LY, Hui VW, Chan HL, Wong GL. Diabetes Mellitus Impacts on the Performance of Hepatocellular Carcinoma Risk Scores in Chronic Hepatitis B Patients. *Clin Gastroenterol Hepatol*. 2023;21:2864-2875.e16.
3. Choi WM*, **Yip TC***, Wong GL, Kim WR, Yee LJ, Brooks-Rooney C, Curteis T, Cant H, Chen CH, Chen CY, Huang YH, Jin YJ, Jun DW, Kim JW, Park NH, Peng CY, Shin HP, Shin JW, Yang YH, Lim YS. Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis. *J Hepatol*. 2023;78:534-542. *co-first authors
4. **Yip TC**, Wong VW, Lai MS, Lai JC, Hui VW, Liang LY, Tse YK, Chan HL, Wong GL. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. *J Hepatol*. 2023;78:524-533.
5. **Yip TC**, Lee HW, Chan WK, Wong GL, Wong VW. Asian perspective on NAFLD-associated HCC. *J Hepatol*. 2022;76:726-734.
6. **Yip TC**, Wong VW, Tse YK, Liang LY, Hui VW, Zhang X, Li GL, Lui GC, Chan HL, Wong GL. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss. *Aliment Pharmacol Ther*. 2021;53:321-331.
7. **Yip TC**, Wong GL, Wong VW, Tse YK, Liang LY, Hui VW, Lee HW, Lui GC, Chan HL. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. *J Hepatol*. 2020;72:847-854.
8. **Yip TC**, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. *Gastroenterology*. 2020;158:215-225.e6.
9. **Yip TC**, Wong GL, Chan HL, Tse YK, Lam KL, Lui GC, Wong VW. HBsAg seroclearance



Seoul International Digestive Disease Symposium 2024

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 20-21, 2024

Grand Walkerhill Seoul, Korea

"Pioneering the future of digestive diseases"



SIDDS 2024

further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. *J Hepatol.* 2019;70:361-370.

10. Hsu YC*, **Yip TC***, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. *J Hepatol.* 2018;69:278-285. *co-first authors